Myriads of cutaneous manifestations with Nilotinib, treated by acitretin – a case report

• Main Authors: Amrita A Hongal, T N Revathi, Seetharampura Ramamurthy Radhika, Kanathur Shilpa
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2020-01-01
• Series: Indian Journal of Drugs in Dermatology
• Subjects: acitretin; chronic myelogenous leukemia; cutaneous side effects; defective keratinization; nilotinib
• Online Access: http://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=2;spage=85;epage=87;aulast=Hongal

A remarkable advancement is been made in the treatment of cancer, through chemotherapeutic drugs like tyrosine kinase inhibitors (TKI), etc. Chemotherapy induced cutaneous side effects are multiple and usually they are underreported. Nilotinib is a second generation TKI, which is approved for imatinib resistant CML. Various cutaneous and its appendageal changes have been noticed with the use of nilotinib usage. Here, we report such case of a 34 year old male, who is a case of CML being treated with Nilotinib for 2.5 years, presented to us with perforating folliculitis, psoriasiform dermatosis, KP like lesions, madarosis and textural changes of scalp hair.